Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: A 15-year study in two large US health systems

Supportive Care in Cancer

Volumn 21, Issue 12, 2013, Pages 3279-3286

  Oster, Gerry ^a   Lamerato, Lois ^b   Glass, Andrew G ^c   Richert Boe, Kathryn E ^c   Lopez, Andrea ^a   Chung, Karen ^d   Richhariya, Akshara ^d   Dodge, Tracy ^c   Wolff, Greg G ^b   Balakumaran, Arun ^d   Edelsberg, John ^a  

^a POLICY ANALYSIS INC PAI   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

^c KAISER PERMANENTE   (United States)

^d AMGEN INC   (United States)

Author keywords

Breast neoplasms; Fractures; Lung neoplasms; Neoplasm metastasis; Prostatic neoplasms; Spinal cord compression; Spontaneous

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; BONE DISEASE; BONE METASTASIS; BREAST CANCER; CANCER RADIOTHERAPY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; ORTHOPEDIC SURGERY; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; SKELETAL RELATED EVENT; SPINAL CORD COMPRESSION; UNITED STATES;

AGED; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; FRACTURES, SPONTANEOUS; HUMANS; INCIDENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SPINAL CORD COMPRESSION; UNITED STATES;

EID: 84889086250     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-013-1887-3     Document Type: Article

References (25)

1. Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:284-293
2. Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165-176
3. Weinfurt KP, Castel LD, Li Y, Timbie JW, Glendenning GA, Schulman KA (2004) Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care 42:164-175
4. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI (2002) Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 168:1005-1007
5. Lage MJ, Barber BL, Harrison DJ, Jun S (2008) The cost of treating skeletal-related events in patients with prostate cancer. Am J Managed Care 14:317-322
6. Delea T, Langer C, McKiernan J, Liss M, Edelsberg J, Brandman J, Sung J, Raut M, Oster G (2004) The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology 67:390-396
7. Rothwell PM (2005) External validity of randomised controlled trials: "to whom do the results of this trial apply?". Lancet 365:82-93
8. Hatoum HT, Lin S, Smith MR, Barghout V, Lipton A (2008) Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases. Cancer 113:1438-1445
9. Nørgaard M, Jensen AØ, Jacobsen JB, Cetin K, Fryzek JP, Sørenson HT (2010) Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol 184:162-167
10. Jensen AØ, Jacobsen JB, Nørgaard M, Yong M, Fryzek JP, Sørenson HT (2011) Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark. BMC Cancer 11:29
11. th edition diagnoses codes of bone metastases and skeletal-related events in breast and prostate cancer patients in the Danish National Registry of Patients. Clin Epidemiol 1:101-108
12. Sun J, Ahn JS, Lee S, Kim JA, Lee J, Park YH, Park HC, Ahn MJ, Ahn YC, Park K (2011) Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases. Lung Cancer 71:89-93
13. Yokomizo A, Koga H, Shinohara N, Miyahara T, Machida N, Tsukino H, Uozumi J, Nishiyama K, Satoh F, Sakai H, Naito S (2010) Skeletal-related events in urological cancer patients with bone metastasis: a multicenter study in Japan. Int J Urol 17:332-336
14. Plunkett TA, Smith P, Rubens RD (2000) Risk of complications from bone metastases in breast cancer: implications for management. Eur J Cancer 36:476-482
15. Domchek SM, Younger J, Finkelstein DM, Seiden MV (2000) Predictors of skeletal complications in patients with metastatic breast carcinoma. Cancer 89:363-368
16. Prentice RL, Kalbfleisch JD (1978) The analysis of failure times in the presence of competing risks. Biometrics 34:541-554
17. Gaynor JJ, Feuer EJ, Tan CC, Wu DH, Little CR, Straus DJ, Clarkson BD, Brennan MF (1993) On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data. J Am Statist Assoc 88:400-409
18. Pepe MS, Mori M (1993) Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data. Stat Med 12:737-751
19. Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD (2004) A note on competing risks in survival data analysis. Br J Cancer 91:1229-1235
20. Gooley TA, Leisenring W, Crowley J, Storer BE (1999) Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18:695-706
21. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B, Zoledronic Acid Prostate Cancer Study Group (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458-1468
22. Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813-822
23. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman JJ (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase qI, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150-3157
24. Stopeck AT, Lipton A, Body JJ, Stegar GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132-5139
25. Rosen LS, Gordon DH, Dugan W Jr, Major P, Eisenberg PD, Provencher L, Kaminski M, Simeone J, Seaman J, Chen BL, Coleman RE (2004) Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100:36-43